AbbVie Slides After J&J Psoriasis Pill Approval Q1

Introduction

AbbVie (NYSE: ABBV) experienced meaningful downward pressure this week as a cluster of confirmed events—an FDA approval for a competitive oral psoriasis therapy, an adverse 340B-related court ruling, and technical breakdowns in the stock—converged. For income and value investors who follow S&P 500 healthcare names closely, these developments change the near-term risk profile for ABBV while leaving its long-term pipeline intact but challenged.

What happened this week

FDA clears J&J’s oral psoriasis pill, Icotyde

On March 18, 2026, the U.S. Food and Drug Administration approved Icotyde, an oral plaque psoriasis treatment from Johnson & Johnson and Protagonist Therapeutics. The approval represents a material competitive event for AbbVie’s leading dermatology franchise, Skyrizi, which is a top sales driver for ABBV. The market reacted quickly: AbbVie shares dropped noticeably on the day of the approval.

Federal appeals court upholds 340B ruling

Also this week, the 5th U.S. Circuit Court of Appeals upheld a Louisiana law that restricts manufacturers from limiting 340B discounts to certain covered entities. That decision narrows pricing flexibility for drug makers and increases potential downside to gross margins and net selling price for medicines across portfolios—an outcome that can pressure earnings for companies with large volumes of outpatient and specialty medicines, like AbbVie.

Market reaction and technical picture

Share-price moves and levels

AbbVie shares dropped to multi‑month lows this week, trading roughly in the low $210s to high $220s range after the news—down from an October 2025 high near $244.81. Short-term traders noted a near-term decline of several percentage points on the Icotyde approval day, reflecting immediate concerns over Skyrizi’s competitive position.

Technicals: moving averages and momentum

Technically, ABBV breached its 50‑day moving average amid the sell-off, with relative strength index (RSI) levels slipping toward neutral‑to‑bearish territory. Momentum indicators such as MACD showed a bearish crossover, signalling that short-term selling pressure had accelerated. For momentum-focused investors, those signals confirm a period of heightened price risk until fresh positive catalysts emerge.

Context: balance sheet and prior financings

Earlier in March 2026, AbbVie completed a public offering of senior notes totaling nearly $8 billion to refinance debt and support corporate purposes. That financing provides liquidity and flexibility, but it also keeps debt service and refinancing in focus for investors evaluating cash flow resilience amid margin pressures and pricing headwinds.

Why these developments matter for ABBV stock

Competitive squeeze on Skyrizi and revenue mix

Skyrizi has been a major revenue engine for AbbVie. The arrival of an oral psoriasis option from a large incumbent like J&J increases prescription choice for physicians and patients and could slow growth for injectable biologics over time. Even if analysts maintain positive medium‑term sales estimates for Skyrizi, the new approval reduces AbbVie’s competitive moat and raises uncertainty around market share and pricing dynamics.

Regulatory and legal pressure on margins

The 340B ruling is a concrete regulatory event that can widen the gap between list prices and realized revenues. For a company that sells many high-cost specialty medicines into hospital and clinic settings, the ruling increases downside to realized unit revenues and could force incremental discounts or contractual concessions.

What investors should watch now

– Pipeline catalysts: upcoming trial readouts and regulatory filings for AbbVie’s next‑generation assets (including obesity and neurology candidates) are the most likely positive catalysts that can offset current dermatology headwinds.
– Sales and market‑share updates: quarterly sales trends for Skyrizi and market share tracking versus new oral options will indicate how much market erosion (if any) is occurring.
– Legal and policy developments: potential appeals or clarifications to the 340B decision could materially affect margin outlook.
– Technical support levels: watch weekly chart support in the low $200s and reactions to the 200‑day moving average for signs of stabilization or further weakness.

Conclusion

The combination of J&J’s Icotyde approval and the 5th Circuit 340B ruling produced a clear, verifiable set of headwinds for AbbVie this week. Investors should treat the pullback as an information‑driven re‑pricing rather than an outright repudiation of ABBV’s longer‑term thesis; however, the new environment raises meaningful near‑term execution and pricing risks. Position sizing, monitoring of upcoming sales reports and pipeline milestones, and attention to legal developments will be key for investors navigating ABBV in the weeks ahead.